Communicable Diseases, Communicable Diseases, Emerging, Emerging Infectious Diseases, Infection
Conditions
Keywords
High Titer Antibodies, Convalescent Volunteers, Apheresis, Males, Quantitative IgG, Natural History
Brief summary
Background: \- There are more emerging infectious diseases recently. Some could affect many people. Some like Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) are caused by new germs. Sometimes known germs suddenly infect new and large areas, like Ebola. Many of these diseases don t have good treatments available. Researchers may be able to develop a treatment by using antibodies against these infections. Objective: \- To collect antibodies from people with high levels of antibodies to the diseases being studied. Eligibility: \- Ages 18-70 years old who weigh at least 110 pounds. They may have been infected with or vaccinated for one of the new infections researchers are studying. Design: * Participants will be screened with medical history and blood tests. Researchers will determine if the participant can have apheresis. * Participants will have apheresis. First, they will be interviewed. Then, a needle will be placed in a vein. Blood will be drawn, and a machine will separate the blood cells from the antibodies and protein. The blood cells will then be returned to the participant through another vein. It takes about 60 minutes for the actual collection. * Participants will be asked to have the procedure at least 3 times. They can participate in up to 20 sessions total as part of this study. There must be at least 7 days between sessions.
Detailed description
The administration of convalescent plasma is often used for treatment of emerging infectious diseases. This natural history protocol will collect plasma from subjects that were vaccinated to or recovered from an emerging infectious disease of interest, in a manner that the plasma can be given to other subjects as a therapeutic. Any administration of plasma to subjects will be under a separate protocol.
Interventions
DRUGPlasma
Plasma
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* INCLUSION CRITERIA: 1. Provide written informed consent before initiation of any study procedures 2. Age \>=8 years old, and \<=70 years old 3. History of a known infection or vaccination towards emerging infectious diseases of interest: * For convalescent subjects, the following criteria must be met: * At least 28 days since the subject was symptomatic from the infection * Afebrile (subjective history acceptable) for at least 28 days * Enrollment must occur within 24 months of illness. * For vaccinated subjects, the following criteria must be met: * Subjects must be at least 14 days after vaccination * If vaccinated on a blinded study, the study must be unblinded and the subject received active product. * Enrollment must occur within 24 months of the last vaccination. * (The above represent the minimum criteria - more restrictive criteria may be listed under disease specific criteria noted in Appendix A) 4\) Weight \>=110 pounds (50 kg) 5\) Adequate peripheral venous access for plasma donation (as judged by the examiner) 6\) Willingness to have samples stored
Exclusion criteria
1. Any sign of active infection (as judged by the investigator), including but not limited to: * Subjective or documented fever (\>38 (Infinite)C) * Cough * Shortness of breath * Diarrhea 2. Pregnancy 3. Meets current blood establishment plasma donation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of units of plasma collected | 5 years after enrollment | The number of units of human plasma collected from volunteers with high titer antibodies for a given emerging infectious disease, that is potentially suitable for infusion into humans as part of a separate treatment study. |
Countries
United States
Outcome results
None listed